Related Experiment Video
Updated: Aug 30, 2025
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Why ARNT Prostate Tumors Responding to Enzalutamide?
Meng Zhang1,2, Thaidy Moreno-Rodriguez1,3, David A Quigley1,3,4
1Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California.
Prostate tumors can become resistant to therapies like enzalutamide. This resistance involves changes in transcription factors and the circadian protein ARNTL, revealing a new therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Circadian Biology
Background:
- Prostate cancer often develops resistance to androgen receptor (AR)-targeted therapies.
- Treatment-induced alterations in transcription factor activity can drive neuroendocrine differentiation.
- Enzalutamide is a second-generation AR-targeted therapy used in prostate cancer treatment.
Discussion:
- This study investigates the molecular mechanisms underlying treatment resistance in prostate cancer.
- It explores the role of transcription factors in promoting neuroendocrine features.
- The research highlights the involvement of circadian clock components in therapy resistance.
Key Insights:
- The circadian protein ARNTL (also known as BMAL1) plays an unexpected role in resistance to enzalutamide.
- ARNTL influences transcriptional changes associated with neuroendocrine prostate cancer.
- This finding offers a novel perspective on overcoming therapeutic resistance.
Outlook:
- Targeting ARNTL may represent a new strategy to overcome enzalutamide resistance.
- Further research into circadian proteins could uncover additional therapeutic targets.
- Understanding these mechanisms may lead to improved treatment outcomes for advanced prostate cancer.
More Related Videos
08:36Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses
Published on: October 24, 2019
12:13Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
